Skip to content
Home/Companies/MedTech/Synoste

Synoste

MedTech·Finland·Exited 2020·Held 5yr
Entry
2015
Hold
5yr
Exit
2020

Who owns Synoste?

Synoste was owned by Evonik Venture Capital through Evonik Venture Capital (2012 vintage) from 2015 to 2020, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-08-10

Evonik Venture Capital
Investor
Evonik Venture Capital
Evonik Venture Capital · 2012 · VC

Key facts

HQFinland
SectorMedTech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2020

More from Evonik Venture Capital

Other portfolio companies in the same fund.

Abolis
Active
BiotechFrance· 2024
JLand Biotech
Active
BiotechChina· 2024
Interface Polymers
Interface Polymers
Active
IndustrialsUK· 2023
SuperC
Active
ClimateTechChina· 2023
Allay Therapeutics
Allay Therapeutics
Active
MedTechUS· 2022
Biograil
Biograil
Active
MedTechDenmark· 2022

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Acufocus, Inc.
Exited 2023
The Carlyle GroupUS
to
Adicon Holdings Limited
Active
The Carlyle GroupUS
Aesynt
Exited 2016
Francisco PartnersUS
to
Alere Medical, Inc.
Active
TA AssociatesUS
Alma Lasers, Ltd.
Alma Lasers, Ltd.
Active
TA AssociatesIsrael
Amedes Group
Active
General AtlanticGermany
Track Synoste

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Synoste?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Synoste.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue